bioRxiv · 10.1101/2020.06.20.163030
Engineered human mesenchymal stem cells as new vaccine platform for COVID-19
Abstract
Recently, there are several routes for COVID-19 vaccine research, yet their weaknesses lie in low efficiency, tolerability, immune adaptability and safety. We describe a new approach to COVID-19 based on engineered human mesenchymal stem cells(hu-MSC), which is like a small protein antigen response device, but will be gradually cleared and degraded by bodys immune system among recognization process. The antibody response results show that this is effective and fast. Furthermore, after several antibody response tests, we obtained an injection of a set of cocktail-like modified human mesenchymal stem cell line. This strategy opened a new avenue for vaccine design against COVID-19.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, J., Jiao, H., Yin, X.. 2020-06-20. Engineered human mesenchymal stem cells as new vaccine platform for COVID-19. https://doi.org/10.1101/2020.06.20.163030
Cite the original work for its findings. Save a collection to share your selection of sources.